A recent study involving 4,000 older adults from the Mr. OS and Ms. OS cohort has elucidated the associations between various biological aging (BA) markers and long-term mortality risk, particularly in an Asian demographic. The study assessed multiple BA markers, including the frailty phenotype, a clinical deficit-based frailty index (FI), biochemical-enhanced FI (comprising eGFR, homocysteine, hsCRP, and 25(OH)-D), and leukocyte telomere length. Mortality data were tracked over a median follow-up of 18.25 years, revealing significant correlations between these markers and overall as well as cause-specific mortality.

The findings indicate that individuals classified as pre-frail and frail had hazard ratios (HRs) of 1.24 and 1.66, respectively, for overall mortality compared to their fit counterparts. Notably, each standard deviation increase in the clinical or biochemical-enhanced FI corresponded to a 22% or 23% increase in overall mortality risk (p < .001). Conversely, longer telomere length was associated with a reduced overall mortality risk (HR per SD: 0.93). While all BA markers, except telomere length, were significantly linked to cardiovascular disease (CVD) mortality, none showed a significant association with cancer mortality. The study also demonstrated that frailty-related markers provided added predictive value for both overall and cause-specific mortality, with improvements in C-index ranging from 0.32% to 7.90%.

This research underscores the potential of integrating multiple BA markers in risk stratification and personalized interventions for older adults. By highlighting the distinct roles of frailty and telomere length in mortality risk, it paves the way for future studies that could refine therapeutic approaches and inform clinical practices in aging populations.

Source: academic.oup.com